Strengthening regulatory systems for medicines in a changed world: where do we go from here?
作者信息
O'Brien Julie, Lumsden Rebecca, Macdonald Judith
机构信息
Global Regulatory Policy and Intelligence, Global Regulatory Affairs, Pfizer Healthcare Ireland, Dublin, Ireland
Global Regulatory Policy and Intelligence, Global Regulatory Affairs, Pfizer Ltd, Tadworth, Surrey, UK.
出版信息
BMJ Glob Health. 2021 Jan;6(1). doi: 10.1136/bmjgh-2020-004680.
Abstract
摘要
相似文献
1
Strengthening regulatory systems for medicines in a changed world: where do we go from here?在不断变化的世界中加强药品监管体系：我们从何去何从？
BMJ Glob Health. 2021 Jan;6(1). doi: 10.1136/bmjgh-2020-004680.
2
COVID-19 and Power in Global Health.COVID-19 与全球卫生中的权力。
Int J Health Policy Manag. 2020 Oct 1;9(10):429-431. doi: 10.34172/ijhpm.2020.72.
3
Has Global Health Law Risen to Meet the COVID-19 Challenge? Revisiting the International Health Regulations to Prepare for Future Threats.全球卫生法是否已奋起应对新冠疫情挑战？重温《国际卫生条例》以应对未来威胁。
J Law Med Ethics. 2020 Jun;48(2):376-381. doi: 10.1177/1073110520935354.
4
Medico-legal issues regarding from the COVID-19 pandemic.关于新冠疫情的法医学问题。 （注：原英文表述不太准确规范，推测可能想表达“Medico-legal issues regarding the COVID-19 pandemic” ）
Med Clin (Barc). 2020 Oct 23;155(8):344-346. doi: 10.1016/j.medcli.2020.06.010. Epub 2020 Jun 25.
5
Declining Public Health Protections within Autocratic Regimes: Impact on Global Public Health Security, Infectious Disease Outbreaks, Epidemics, and Pandemics.专制政权下公共卫生保护措施的减少：对全球公共卫生安全、传染病暴发、流行病和大流行的影响。
Prehosp Disaster Med. 2020 Jun;35(3):237-246. doi: 10.1017/S1049023X20000424. Epub 2020 Apr 8.
6
Political interference in public health science during covid-19.新冠疫情期间政治对公共卫生科学的干预。
BMJ. 2020 Oct 6;371:m3878. doi: 10.1136/bmj.m3878.
7
Guiding Principles of Global Health Governance in Times of Pandemics: Solidarity, Subsidiarity, and Stewardship in COVID-19.大流行时期全球卫生治理的指导原则：新冠疫情中的团结、辅助性和管理职责
Am J Bioeth. 2020 Jul;20(7):212-214. doi: 10.1080/15265161.2020.1779862.
8
"Slow research" in the time of Covid-19.Covid-19 时期的“缓慢研究”。
Indian J Med Ethics. 2020 Jul-Sep;V(3):212-214. doi: 10.20529/IJME.2020.072.
9
Virtual health care in the era of COVID-19.新冠疫情时代的虚拟医疗保健
Lancet. 2020 Apr 11;395(10231):1180-1181. doi: 10.1016/S0140-6736(20)30818-7.
10
Why the COVID-19 pandemic should be a call for action to advance equitable access to medicines.为何新冠疫情应成为推动药品公平可及的行动号角。
BMC Med. 2020 Jun 25;18(1):193. doi: 10.1186/s12916-020-01661-3.
引用本文的文献
1
Suitability of paediatric legislation beyond the USA and Europe: a qualitative study on access to paediatric medicines.美国和欧洲以外地区儿科立法的适用性：关于儿科药物可及性的定性研究
BMJ Public Health. 2024 Feb 7;2(1):e000264. doi: 10.1136/bmjph-2023-000264. eCollection 2024 Jun.
2
Understanding the regulatory-procurement interface for medicines in Africa via publicly available information on standards, implementation, and enforcement in five countries.通过五个国家关于标准、实施和执行的公开信息来了解非洲药品监管与采购之间的关系。
J Pharm Policy Pract. 2025 Jan 9;18(1):2436898. doi: 10.1080/20523211.2024.2436898. eCollection 2025.
3
Evaluation of the Regulatory Review Process of the Zambia Medicines Regulatory Authority: Challenges and Opportunities.赞比亚药品监管局监管审查流程评估：挑战与机遇
Ther Innov Regul Sci. 2025 Mar;59(2):304-318. doi: 10.1007/s43441-024-00730-6. Epub 2024 Dec 27.
4
Good manufacturing practice inspections conducted by Tanzania medicines and medical devices authority: a comparative study of two fiscal years from 2018 to 2020.坦桑尼亚药品和医疗器械管理局进行的药品生产质量管理规范检查：2018年至2020年两个财政年度的比较研究
J Pharm Policy Pract. 2024 Sep 16;17(1):2399722. doi: 10.1080/20523211.2024.2399722. eCollection 2024.
5
Regulatory agilities impacting review timelines for Pfizer/BioNTech's BNT162b2 mRNA COVID-19 vaccine: a retrospective study.影响辉瑞/生物科技公司BNT162b2 mRNA新冠疫苗审评时间的监管灵活性：一项回顾性研究
Front Med (Lausanne). 2023 Nov 8;10:1275817. doi: 10.3389/fmed.2023.1275817. eCollection 2023.
6
Global inequity creates local insufficiency: A qualitative study of COVID-19 vaccine implementation challenges in low-and-middle-income countries.全球不平等导致本地供应不足：对 COVID-19 疫苗在中低收入国家实施挑战的定性研究。
PLoS One. 2023 Feb 13;18(2):e0281358. doi: 10.1371/journal.pone.0281358. eCollection 2023.
7
Regulatory reliance for convergence and harmonisation in the medical device space in Asia-Pacific.亚太地区医疗器械领域趋同与协调的监管依赖
BMJ Glob Health. 2022 Aug;7(8). doi: 10.1136/bmjgh-2022-009798.
8
Dynamic Regulatory Assessment: evolving the European Regulatory Framework for the Benefit of Patients and Public Health-an EFPIA View.动态监管评估：为了患者和公众健康的利益而不断发展的欧洲监管框架——EFPIA 的观点。
Clin Ther. 2022 Jan;44(1):132-138. doi: 10.1016/j.clinthera.2021.11.001. Epub 2021 Nov 27.
本文引用的文献
1
COVID-19: A Catalyst to Accelerate Global Regulatory Transformation.新冠疫情：加速全球监管变革的催化剂
Clin Pharmacol Ther. 2021 Jun;109(6):1390-1392. doi: 10.1002/cpt.2046. Epub 2020 Sep 29.
2
COVID-19 must catalyse changes to clinical development.新冠疫情必须推动临床开发的变革。
Nat Rev Drug Discov. 2020 Oct;19(10):653-654. doi: 10.1038/d41573-020-00149-2.
3
The WHO Global Benchmarking Tool: a game changer for strengthening national regulatory capacity.世卫组织全球基准工具：加强国家监管能力的游戏规则改变者。
BMJ Glob Health. 2020 Aug;5(8). doi: 10.1136/bmjgh-2020-003181.
4
Regulating Medicines in a Globalized World With Increased Recognition and Reliance Among Regulators: A National Academies Report.《在监管机构之间认可度和依赖度不断提高的全球化世界中对药品进行监管：一份美国国家科学院报告》
JAMA. 2020 Jul 14;324(2):145-146. doi: 10.1001/jama.2019.21793.
5
Building a Better Approach for the Benefit of Patients: 10 Pillars to Strengthen Regulatory Review Systems Globally.为了患者的利益，建立更好的方法：加强全球监管审查系统的 10 大支柱。
Ther Innov Regul Sci. 2020 Mar;54(2):283-292. doi: 10.1007/s43441-019-00055-9. Epub 2020 Jan 6.
Zotero 插件